SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 25, 2005
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| 000-23265 | 94-3267443 | |
| (Commission File Number) | (IRS Employer ID Number) |
| 8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina | 27615 | |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On April 25, 2005, Salix Pharmaceuticals, Ltd. issued a press release announcing that results of five investigator-initiated trials of rifaximin will be presented at Digestive Disease Week 2005, which will be held May 14-19, 2005 in Chicago, IL. A copy of this exhibit is attached.
| Item 9.01. | Financial Statements and Exhibits. |
| (c) | Exhibits |
| Exhibit No. | Description | |
| 99.1 | Press release dated April 25, 2005. | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
Date: April 25, 2005 | /s/ Adam C. Derbyshire | |||||||
Adam C. Derbyshire | ||||||||
Senior Vice President and Chief Financial Officer | ||||||||
